|
Re: Dr. Slamon et al have done it again--found a new target in her2+ br cancers (agai
"trastuzumab can inhibit proliferation of HER2-overexpressing breast cancer cells by reactivating FOXO1A through inhibition of the PI3K/Akt pathway."
Good thing there are currently available ways to inhibit PI3k/Akt:
Zoledronate Acid (Zometa)
Tamoxifen
Green Tea
IP6
Honokiol
Apigenin
|